1. P022 Transcriptional biomarkers for vedolizumab therapy response in patients with moderate to severe Ulcerative Colitis. (21st January 2022) Authors: Arosa García, L; Camba-Gómez, M; Calviño-Suárez, C; Bastón-Rey, I; Ferreiro-Iglesias, R; Porto, M; Nieto-García, L; Domínguez-Muñoz, J E; Barreiro-de Acosta, M; Conde-Aranda, J Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P689 Predictive transcriptional signatures associated to vedolizumab therapy response in patients with ulcerative colitis. (30th January 2023) Authors: Camba Gómez, M; Arosa, L; Calviño-Suárez, C; Bastón-Rey, I; Ferreiro-Iglesias, R; Porto, M; Nieto, L; Domínguez-Muñoz, J E; Barreiro-de Acosta, M; Conde-Aranda, J Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i818 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗